Exabis Library
Welcome to the e-CCO Library!
P389: The value of oxidative stress parameters to predict histological severity in ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P390 New features of molecular diagnostics of the regulation of molecular apoptotic pathway in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P390: Diverting Loop Ileostomy in Medically Refractory Crohn's Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P390: Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn´s disease: multicentric experience in the Basque Country and Navarre
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P390: Methotrexate is not superior to placebo in maintaining remission in patients with ulcerative colitis: results from the MERIT-UC study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P390: Open-label study to evaluate the pharmacokinetics of fidaxomicin in inflammatory bowel disease patients with Clostridium difficile infection (the PROFILE study): pharmacokinetics analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P390: The impact of anti-TNF therapy in adjuvant setting on postoperative recurrence patterns over decades in complicated Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P390: To double dose or not to double dose? That is the question: Single centre experience in the use of infliximab antibodies and levels in a paediatric IBD (pIBD) cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P390: Ustekinumab modulates IL-12 and IL-23-related cell type-specific inflammatory transcriptional states in Ulcerative Colitis induction therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P391 Side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn’s ileitis: single-centre long-term outcome
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P391: Antibiotics in pediatric Inflammatory Bowel Diseases: a systematic review
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P391: Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P391: Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United Kingdom
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P391: Gender differences in adalimumab continuation rates: Results of a Crohn’s disease cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P391: Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 phase 3 clinical trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P391: The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn’s disease but not in ulcerative colitis. A nationwide study from the Eneida registry
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P391: Unpacking the different popular diets for pediatric Crohn's disease - concerns around nutritional adequacy
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P392 Initial experience with fibrin glue combined with infliximab treatment of postoperative anastomotic fistula in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P392: A mobile application to monitor Inflammatory Bowel Disease patients during intravenous biologic treatment: Results of a feasibility study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P392: Body mass index has no effect on treatment response in Crohn's disease patients with moderate disease activity who receive adalimumab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM